Category «Phase 2»

CENTANAFADINE

It’s only fair to share… Centanafadine; UNII-D2A6T4UH9C; EB-1020 free base; D2A6T4UH9C; 924012-43-1 CTN SR; EB-1020; EB-1020 SR WO 2007016155 Molecular Formula: C15H15N Molecular Weight: 209.292 g/mol Phase II Attention-deficit hyperactivity disorder No development reported Major depressive disorder; Neuropathic pain Most Recent Events 20 Dec 2016 Neurovance plans a phase III trial for Attention-deficit hyperactivity disorder 27 Jul 2016 Efficacy data from …

PIMODIVIR, VX 787

It’s only fair to share… PIMODIVIR VX-787, JNJ-63623872, JNJ-872, VRT-0928787, VX-787, VX 787,  VX787,  JNJ-872, JNJ 872, JNJ872, VRT-0928787, VRT 0928787, VRT0928787, pimodivir (2S,3S)-3-{[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino}bicyclo[2.2.2]octane-2-carboxylic acid (2S,3S)-3-((2-(5-fluoro-1H-pyrrolo[2,3-b]pyridm-3-yl)-5- fluoropyrimidin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylic acid (2S,3S)-3-((5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylic Acid MF C20H19F2N5O2, MW 399.4018 CAS 1629869-44-8 PHASE 2 Originator Vertex Pharmaceuticals Developer Janssen Pharmaceuticals Mechanism Of Action Viral polymerase inhibitor, Viral protein inhibitor Who Atc Codes …

Filgotinib

It’s only fair to share… Filgotinib C21H23N5O3S MW425.504 Elemental Analysis: C, 59.28; H, 5.45; N, 16.46; O, 11.28; S, 7.54 1206161-97-8 Cyclopropanecarboxamide, N-[5-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]- G146034 GLPG0634 N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Galapagos Nv INNOVATOR IL-6 antagonist; Jak1 tyrosine kinase inhibitor; Tyk2 tyrosine kinase inhibitor; Jak3 tyrosine kinase inhibitor; Jak2 tyrosine kinase inhibitor Autoimmune disease; Cancer; Colitis; Crohns disease; Inflammatory disease; Neoplasm; …

Verubecestat (MK-8931)

It’s only fair to share… Verubecestat (MK-8931) Merck Alzheimer’s drugs Verubecestat (MK-8931) is an oral β- amyloid precursor protein cleaving enzyme (BACE1 or β-secretase enzyme) inhibitor, is currently in Phase III clinical trials Verubecestat MK 8931, MK-8931, SCH 900931 2-Pyridinecarboxamide, N- (3 – ((5R) -3-amino-5,6-dihydro-2,5-dimethyl-1 , 1-dioxido-2H-1,2,4-thiadiazin-5-yl) -4-fluorophenyl) -5-fluoro- N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide CAS : 1286770-55-5 C17 H17 …

BMS-741672

It’s only fair to share… BMS-741672 N-((1R,2S,5R)-5-(Isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide BMS-741672 N-((lR,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide; C25 H33 F3 N6 O2, 506.56 Acetamide, N-[(1R,2S,5R)-5-[methyl(1-methylethyl)amino]-2-[(3S)-2-oxo-3-[[6-(trifluoromethyl)-4-quinazolinyl]amino]-1-pyrrolidinyl]cyclohexyl]- CAS 1004757-96-3 PHASE 2, , Treatment of Type 2 Diabetes, Agents for Neuropathic Pain Chemokine CCR2 (MCP-1 Receptor) Antagonists Molecular Formula: C25H33F3N6O2 Molecular Weight: 506.574 g/mol Michael G. Yang, Robert J. Cherney Original Assignee Bristol-Myers Squibb Company Michael G. Yang, …

BMS 986001, Censavudine, Festinavir

It’s only fair to share… BMS 986001 Censavudine, Festinavir Has anti-HIV activity. IN PHASE 2 CAS: 634907-30-5, UNII: 6IE83O6NGA, OBP 601, 4′-Ethynyl D4T, 4′-Ed4T, TDK-4-114 Molecular Formula, C12-H12-N2-O4, Molecular Weight, 248.2368 2′,3′-Didehydro-3′-deoxy-4′-ethynylthymidine,  1-((2R,5R)-5-Ethynyl-5-(hydroxymethyl)-2H-furan-2-yl)-5-methyl-pyrimidine-2,4-dione,  2′,3′-Didehydro-3′-deoxy-4′-ethynylthymidine INNOVATOR= YALE UNIVERSITY Festinavir is a nucleoside reverse transcriptase inhibitor (NRTI) which is being developed for the treatment of HIV infection. The drug has shown considerable efficacy in …

Glecaprevir (ABT-493)

It’s only fair to share… Glecaprevir (ABT-493), A-1282576.0 (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-((1R,2R)-2-(difluoromethyl)-1-((1-methylcyclopropane-1-sulfonyl)carbamoyl)cyclopropyl)-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta(18,19)(1,10,17,3,6)trioxadiazacyclononadecino(11,12-b)quinoxaline-10-carboxamide Cyclopropanecarboxamide, N-((((1R,2R)-2-((4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl)oxy)cyclopentyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)-, cyclic (1->2)-ether, (1R,2R)- CAS RN: 1365970-03-1 UNII: K6BUU8J72P Molecular Formula, C38-H46-F4-N6-O9-S Molecular Weight, 838.8724 Classification Code, Treatment of Chronic Hepatitis C Infection (1R,14E,18R,22R,26S,29S)-N-[(1R,2R)-2-(Difluormethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-13,13-difluor-26-(2-methyl-2-propanyl)-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetraazapent ;acyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5(10),6,8,11,14-hexaen-29-carboxamid (1R,14E,18R,22R,26S,29S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-13,13-difluoro-26-(2-methyl-2-propanyl)-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetraazape ;ntacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5(10),6,8,11,14-hexaene-29-carboxamide Class Antivirals (small molecules) Mechanism Of Action Hepatitis C virus NS3 protein inhibitors Who Atc Codes J05A-E (Protease inhibitors) Ephmra Codes J5B1 (Viral hepatitis …

PF-04136309

It’s only fair to share… PF 4136309 PF4136309; PF 4136309; PF-4136309; PF04136309; PF4136309; PF-04136309; INCB8761; INCB 8761; INCB-8761 (S)-N-(2-(3-((4-hydroxy-4-(5-(pyrimidin-2-yl)pyridin-2-yl)cyclohexyl)amino)pyrrolidin-1-yl)-2-oxoethyl)-3-(trifluoromethyl)benzamide N-[2-[(3S)-3-[[trans-4-Hydroxy-4-[5-(2-pyrimidinyl)-2-pyridinyl]cyclohexyl]amino]-1-pyrrolidinyl]-2-oxoethyl]-3-(trifluoromethyl)benzamide N-[2-((3S)-3-[4-hydroxy-4-(4-pyrimidin-2-ylphenyl)cyclohexyl]aminopyrrolidin-1-yl)-2- oxoethyl]-3-(trifluoromethyl)benzamide 1341224-83-6 MF: C29H31F3N6O3 MW: 568.24097 CC chemokine receptor 2 (CCR2) antagonist Pfizer Limited Gary Burgess PF-4136309, also known as INCB8761, is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating …

REMOGLIFLOZIN ETABONATE

It’s only fair to share… REMOGLIFLOZIN ETABONATE 5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside, ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-oxan-2-yl]methyl carbonate  https://clinicaltrials.gov/show/NCT02537470   UNII:TR0QT6QSUL CAS 442201-24-3 189075  BHV-091009  GSK-189075  GSK-189075A  KGT-1681  BHV Pharma  Kissei (Originator)  , GlaxoSmithKline Remogliflozin etabonate Phase II A SGLT-2 antagonist potentially for the treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity. GSK-189075; GSK-189075A Molecular FormulaC26H38N2O9 Average mass522.588 Remogliflozin etabonate (INN/USAN)[1] …

RPL 554

It’s only fair to share… RPL-554 Molecular FormulaC26H31N5O4 Average mass477.555 RPL 554 Urea, N-[2-[(2E)-6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]- (2-[(2E)-9,10-DIMETHOXY-4-OXO-2-[(2,4,6-TRIMETHYLPHENYL)IMINO]-2H,3H,4H,6H,7H-PYRIMIDO[4,3-A]ISOQUINOLIN-3-YL]ETHYL)UREA 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea {2-[(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H,3H,4H,6H,7H-pyrimido[4,3-a]isoquinolin-3-yl]ethyl}urea 2-[4-keto-9,10-dimethoxy-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[4,3-a]isoquinolin-3-yl]ethylurea 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[4,3-a]isoquinolin-3-yl]ethylurea 298680-25-8  CAS UNII:3E3D8T1GIX CFTR stimulator; PDE 3 inhibitor; PDE 4 inhibitor RPL-554 is a mixed phosphodiesterase (PDE) III/IV inhibitor in phase II clinical development at Verona Pharma for the treatment of asthma, allergic rhinitis, chronic obstructive …